In February this year, a Nature editorial defended “curiosity-driven research” against governments seeking clearer alignment between public research funding and political priorities. Its warning was reasonable: if science is required to promise immediate economic or social returns, it risks losing the freedom that makes unexpected discovery possible.
Fair enough. But the phrase “curiosity-driven research” deserves some curiosity of its own.
It sounds neutral, even noble. Who could object to curiosity? Yet the term carries an implicit hierarchy. Some forms of inquiry appear to arise from pure intellectual wonder. Others are described as applied, strategic, policy-facing or problem-solving.
Curiosity is romanticised when it investigates particles, pathways and proteins. It becomes somehow less pristine when it investigates payment systems, delivery models, regulatory capture, inequality or power. This hierarchy is rarely stated outright. The laboratory has become the symbolic home of unconstrained inquiry. Systems research sounds managerial. Basic science asks fundamental questions. Implementation research deals with what happens afterwards.
But scientific curiosity does not only live in a building with a lab bench.
There is curiosity in asking why maternal mortality remains high in wealthy countries. There is curiosity in understanding why certain cancers cluster in particular communities. There is curiosity in examining why some health systems readily pay for expensive treatment while neglecting prevention. There is intellectual ambition in studying institutions.
And there is something odd about a scientific culture that regards the molecular mechanisms of disease as inherently more fundamental than the mechanisms determining who becomes ill, who receives care and who does not.
The defence of curiosity-driven science usually presents the threat as external. Governments may become impatient. Ministers may demand politically convenient results. Funding agencies may insist on measurable impact. Those threats are real.
But scientific inquiry is also directed from within.
Universities decide which fields receive chairs and laboratories. Funding panels decide which questions appear promising. Journals establish hierarchies of prestige. Promotion systems reward particular forms of output. Commercial markets make some areas of discovery vastly more attractive than others.
None of this requires anyone to issue an instruction saying: study this, not that. The signal is quieter. Questions like these lead somewhere. Questions like those do not.
Over time, entire ecosystems of expertise, infrastructure and reputation accumulate around some forms of inquiry. Other questions remain thinly funded, methodologically fragmented or professionally risky.
Science is therefore never simply curiosity-driven. Institutions determine which curiosities can become careers. Health research has seen a much larger version of this problem before.
More than three decades ago, the enormous mismatch between health research investment and the distribution of disease became known as the “10/90 gap”: less than 10 per cent of research spending was said to address conditions accounting for around 90 per cent of the global burden of ill health. The numbers belong to another era and should not be treated as a contemporary estimate. WHO itself later described the 10/90 gap as shorthand for a profound imbalance in health research investment. But the formulation captured something that remains useful.
The 10/90 gap was usually described as a funding gap. But it was also a map of what the research system had learned to find interesting.
Research capacity, universities, laboratories, commercial markets and scientific networks were concentrated in particular countries and around particular problems. Those structures did not merely determine where research happened. They helped determine which questions could develop into major programmes of inquiry.
Curiosity follows infrastructure. It follows markets. It follows prestige.
That does not make the curiosity of individual researchers insincere. A scientist can be genuinely fascinated by a receptor, a pathway or a rare condition. But whether that fascination becomes a laboratory, a twenty-year research programme, a specialist journal and a recognised field depends on much more than intellectual wonder.
The opposite of political direction is therefore not an absence of direction. It may simply be direction that has become invisible.
The problem is not only that research follows geography. Even within well-funded health systems, some questions acquire scientific gravity while others do not. Oral health research offers a particularly clear example. Dentistry has developed extraordinary scientific sophistication. Researchers engineer new biomaterials, refine implant surfaces, analyse molecular pathways, improve imaging and now train artificial intelligence systems to identify disease. These are serious scientific achievements.
But compare that ingenuity with the much thinner research landscape around the systems that determine whether populations retain their teeth in the first place.
Why do some health systems pay readily for extraction but poorly for prevention? Why does dental coverage remain separated from other health coverage in so many countries? Why are workforce models still organised around patterns of care developed generations ago? Why is the commercial environment producing and promoting sugar-rich products so much more powerful than the systems trying to prevent the disease they cause? Why do inequalities in oral disease remain so strikingly predictable?
These are not less fundamental questions.
A field can become extraordinarily sophisticated in understanding how to restore an individual tooth while remaining surprisingly incurious about why millions of people predictably lose them. The ingenuity is real. So is the avoidable suffering that ingenuity does not reach.
That is not an argument against laboratory science. Nor is it an argument that research funding should mechanically follow disease burden. A healthy scientific ecosystem needs work whose usefulness cannot yet be predicted. Some of the most important discoveries began without a clear application. Science would become poorer if every grant application had to promise an intervention, a product or a policy outcome.
But the inverse deserves scrutiny too. When a research system repeatedly directs talent and resources towards particular kinds of questions, it should not describe the resulting pattern simply as the spontaneous expression of curiosity.
Public funding adds another layer. Collective resources should protect intellectual autonomy. But autonomy is not the same as insulation from public purpose. A research portfolio can preserve ample room for uncertain discovery while still asking whether major areas of suffering, inequality and system failure receive serious intellectual attention.
The framing of basic versus applied research is misleading. The real question is between visible and invisible direction of research curiosity. Political direction is easy to recognise. A government announces a priority, establishes a programme and moves money towards it.
Scientific and academic direction is harder to see. It operates through what attracts funding, what generates publications, what earns promotion, what builds institutions and what young researchers learn to regard as an important question.
One looks like intervention. The other looks like freedom.
That is why the language of “curiosity-driven research” can become protective. It places certain forms of inquiry beyond the need to explain why their questions became central while others remained peripheral. And once those hierarchies are established, defending curiosity can inadvertently become a defence of the accumulated choices that produced them.
The challenge is to widen our understanding of where intellectual seriousness resides. Curiosity can interrogate molecules. It can also interrogate markets, institutions, professional power and inequality. It can ask how disease works inside a cell and why its consequences are distributed so predictably across society.
The future of health research is not a choice between freedom and mission. It is a question of whose questions we have decided are worthy of being called curiosity at all. And that is a question curiosity itself should be asking.
I really liked your point that studying payment or delivery is treated as less intellectually serious than studying a pathway, even when those systems determine whether the discovery reaches anyone. Implementation success often looks like an absence: no missed appointment, delayed treatment, or preventable admission. How do we make that kind of knowledge as visible and fundable as a laboratory result?
It takes us beyond the romantic idealism of “pure curiosity” and into the real world—where curiosity, like everything else, is shaped by funding, prestige, infrastructure, markets and academic hierarchies.
A timely reminder🎯